Palbociclib clinical trials
Also written Ibrance, PD-0332991 and PD 332991.
ClinicalTrials.gov finds 443 studies for palbociclib. How that becomes 225 here
Every study that search finds has been read, apart from the 3 newest, to see whether and how it gives palbociclib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 443Found by its intervention search · See all 443 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 375 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −6
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaNCT03531645 · Abemaciclib, a different CDK4/6 inhibitorReport a problem
- Treatment After Palbociclib-containing RegimensNCT04517318 · Earlier treatment, not given in this studyReport a problem
- Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerNCT05065411 · Earlier treatment, not given in this studyReport a problem
- Chidamide in Combination With Abemaciclib and Endocrinotherapy(Doctor's Choice) in Breast Cancer Patients Previously Treated With PalbociclibNCT05464173 · Earlier treatment, not given in this studyReport a problem
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT05696626 · Earlier treatment, not given in this studyReport a problem
- Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerNCT07558733 · Earlier treatment, not given in this studyReport a problem
- −1New since the last reading, not read yet
- 436Give palbociclib to participants
- −73Observe patients on it, or give it outside a trial
- −7Compare another treatment with it
- −131Give it beside what is tested
- 225Test it: the count on this site
Get an email when these change. Save the palbociclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 3 Feb 2015 · IBRANCE · NDA 207103 (FDA, Drugs@FDA)
- European Union
- 9 Nov 2016 · Ibrance · EMEA/H/C/003853 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Ibrance
- 92
Studies by the year they started
225 studies that test it; most in 2017 (27)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 13 |
| 2014 | 21 |
| 2015 | 22 |
| 2016 | 17 |
| 2017 | 27 |
| 2018 | 21 |
| 2019 | 17 |
| 2020 | 8 |
| 2021 | 9 |
| 2022 | 13 |
| 2023 | 11 |
| 2024 | 17 |
| 2025 | 9 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 43 · Other 182
Pfizer (35) · National Cancer Institute (NCI) (9) · Washington University School of Medicine (6) · Dana-Farber Cancer Institute (6) · Abramson Cancer Center at Penn Medicine (4) · Georgetown University (4) · Alliance Foundation Trials, LLC. (3) · M.D. Anderson Cancer Center (3)
Often tested with
Tested in the same studies.
Ribociclib (15) · Letrozole (14) · Olaparib (13) · Trastuzumab (10) · Pertuzumab (8) · Binimetinib (7) · Crizotinib (7) · Fulvestrant (7)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Palbociclib is the comparator. A study of two new drugs counts under both.
- 1Atirmociclib · Pfizer · next primary completion Jan 2029
- 1HRS-6209 · Jiangsu HengRui Medicine Co., Ltd. · next primary completion Jul 2031
- 1CDK4 Inhibitor BGB-43395 · BeOne Medicines · next primary completion Apr 2029
New treatments tested with it · 8 most studied
New when their studies opened, with palbociclib beside them; studies of each.
Reaching primary completion within a year · 21, 1 in phase 3
Studies that test palbociclib, phase 3 first.
- Dec 2026Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerPhase 3 · ETOP IBCSG Partners Foundation
- Nov 2026Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Phase 1/2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorPhase 2 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Dec 2026Umbrella Biomarker-Guided Therapy in NPCPhase 2 · Sun Yat-sen University
- Dec 2026Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast CancerPhase 2 · Xinhong Wu, PhD
- Dec 2026A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Phase 1/2 · Merck Sharp & Dohme LLC
- Dec 2026Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerPhase 2 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
- Dec 2026Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPhase 2 · Tianjin Medical University Second Hospital
- Jan 2027Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast CancerPhase 2 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Studies
Open first, then newest update. How each study uses palbociclib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 225
- Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruitingPhase 3Washington University School of MedicineNCT04966481Added to cetuximab in head and neck cancerWritten as PalbociclibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377One matched combination in ComboMATCHWritten as PalbociclibReport a problem
- Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaNot yet recruitingPhase 1/2Second Affiliated Hospital of Nanchang UniversityNCT07926607Written as PalbociclibReport a problem
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06126276Added to neratinib in HER2-positive tumours (ComboMATCH)Written as PalbociclibReport a problem
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingPhase 3American Society of Clinical OncologyNCT06377852Titrated dosing against the indicated doseWritten as Palbociclib 125mgReport a problem
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationEarly Phase 1AHS Cancer Control AlbertaNCT05432518One of five matched drugs in recurrent glioblastomaWritten as PalbociclibReport a problem
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT04693468Added to talazoparib in one armReport a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052One CDK4/6 option, chemotherapy exemption in older womenReport a problem
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06843967With mirdametinib in liposarcomaWritten as PalbociclibReport a problem
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498One CDK4/6 option added to elacestrantWritten as elacestrant, palbociclib, abemaciclib, ribociclibReport a problem
- Novel Molecular Targets and Innovative Therapeutic Perspective in MedulloblastomaRecruitingEarly Phase 1Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06959979One CDK4/6 option in medulloblastomaReport a problem
- Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruitingPhase 2Massachusetts General HospitalNCT02896335Alone or with pembrolizumab in brain metastasesWritten as PalbociclibReport a problem
- Palbociclib and Pembrolizumab in SarcomaRecruitingPhase 1John RiethNCT06113809Before pembrolizumab in sarcomaWritten as PalbociclibReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One CDK4/6 option in an HR-positive salivary cohortReport a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606One matched drug in a profiling trial (CAPTUR)Written as PalbociclibReport a problem
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingPhase 1Thomas Jefferson UniversityNCT05627232Added before tazemetostat and CPX-351 in one partWritten as PalbociclibReport a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07299890With HER2 blockade and exemestane before surgeryWritten as Trastuzumab and Pertuzumab Combination with Palbociclib and ExemestaneReport a problem
- An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast CancerNot yet recruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT07300215With HER2 blockade and exemestane, response-adapted, before surgeryReport a problem
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 1/2West China HospitalNCT06753747With afatinib in esophageal cancerWritten as PalbociclibReport a problem
- Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial CarcinomaRecruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06364956With tislelizumab before bladder surgeryReport a problem
See all 225 studies that test palbociclib →
Behind its US label · 2 — the studies the FDA label of IBRANCE describes
From the Clinical Studies section of IBRANCE (2026-07), as openFDA has it. A study the site does not hold is left out.
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingPhase 3Alliance Foundation Trials, LLC.NCT02947685Report a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 2/3Hoffmann-La RocheNCT04191499Report a problem
Tested on its own · 42 — no other medicine in its arm
- Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNot applicableHenan Cancer HospitalNCT06478927Alone in later-line liver cancerWritten as Palbociclib capsulesReport a problem
- Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.RecruitingPhase 2Grupo Espanol de Investigacion en SarcomasNCT03242382Alone in sarcomas with CDK4 overexpressionWritten as PalbociclibReport a problem
- Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439201Alone with CCND amplification (NCI-MATCH)Written as PalbociclibReport a problem
- Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine TherapyActive, not recruitingPhase 2University of NebraskaNCT05069038With endocrine therapy before surgeryWritten as Palbociclib 125mgReport a problem
- Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06390839Alone with CDK4 or CDK6 amplification (NCI-MATCH)Written as PalbociclibReport a problem
- Adjuvant Palbociclib in Elderly Patients With Breast CancerActive, not recruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT03609047Adjuvant with endocrine therapy against chemotherapyWritten as PalbociclibReport a problem
- Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedPhase 2National Cancer Institute (NCI)NCT03526250One subprotocol of Pediatric MATCHWritten as PalbociclibReport a problem
- Palbociclib in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT02905318Alone in castration-resistant prostate cancerWritten as PalbociclibReport a problem
- Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for SurgeryTerminatedPhase 2Georgetown UniversityNCT03535506Before surgery for DCISWritten as PalbociclibReport a problem
- Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedPhase 2Institut BergoniéNCT01907607Alone in GISTWritten as PD 0332991Report a problem
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver CancerCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT01356628Alone in liver cancerWritten as PD-0332991Report a problem
- Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB PreservedCompletedPhase 2Grupo Español de Investigación en NeurooncologíaNCT02530320Alone in oligodendrogliomaWritten as PalbociclibReport a problem
- Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mgCompletedPhase 4MegalabsNCT06331715Generic capsule against Ibrance, bioequivalenceWritten as Palbociclib 125mgReport a problem
- A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryCompletedPhase 3GBG Forschungs GmbHNCT01864746Against placebo for residual disease after chemotherapy (PENELOPE-B)Written as Palbociclib PD-0332991Report a problem
- Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)CompletedPhase 2Jules Bordet InstituteNCT03065621With endocrine therapy before surgery, biomarkers studiedWritten as PalbociclibReport a problem
- CDK4/6 Inhibition in Locally Advanced/Metastatic ChordomaCompletedPhase 2University Hospital HeidelbergNCT03110744Alone in chordomaWritten as PalbociclibReport a problem
- Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent ThromboinflammationWithdrawnPhase 2biotx.ai GmbHNCT05371275Alone in hospitalised COVID-19Written as PalbociclibReport a problem
- Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast CancerCompletedPhase 2/3Georgetown UniversityNCT02692755Safety in African American womenWritten as Palbociclib + Letrozole or FulvestrantReport a problem
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerCompletedPhase 2Abramson Cancer Center at Penn MedicineNCT01037790Alone across several cancersWritten as PD-0332991Report a problem
- A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionCompletedPhase 2Jonsson Comprehensive Cancer CenterNCT01536743Alone in ovarian cancerWritten as PD0332991Report a problem
Showing 20 of 42. See all 42 →
Tested with established drugs · 58 — they are given beside it
- Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruitingPhase 3Washington University School of MedicineNCT04966481Added to cetuximab in head and neck cancerWritten as PalbociclibReport a problem
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06126276Added to neratinib in HER2-positive tumours (ComboMATCH)Written as PalbociclibReport a problem
- Palbociclib and Pembrolizumab in SarcomaRecruitingPhase 1John RiethNCT06113809Before pembrolizumab in sarcomaWritten as PalbociclibReport a problem
- Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07061717High dose with hydroxychloroquine against the standard doseWritten as Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qdReport a problem
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingPhase 2National Taiwan University HospitalNCT05766410Against ribociclib and abemaciclib, immune effects comparedWritten as PalbociclibReport a problem
- A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]CompletedPhase 3PfizerNCT02297438Added to letrozole in Asian patients (PALOMA-4)Written as PalbociclibReport a problem
- A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT05468697Added to belzutifan in kidney cancerWritten as PalbociclibReport a problem
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingPhase 3Alliance Foundation Trials, LLC.NCT02947685On the US labelAdded to anti-HER2 and endocrine therapy (PATINA)Written as palbociclibReport a problem
- To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)CompletedPhase 2ETOP IBCSG Partners FoundationNCT03644186With letrozole and HER2 blockade against paclitaxel (TOUCH)Written as PalbociclibReport a problem
- PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerActive, not recruitingPhase 2Washington University School of MedicineNCT01723774With anastrozole before breast surgeryWritten as PD0332991Report a problem
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03573648Added to endocrine therapy before surgeryWritten as PalbociclibReport a problem
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive, not recruitingPhase 3ETOP IBCSG Partners FoundationNCT03820830Added to endocrine therapy for locoregional recurrence (POLAR)Written as Palbociclib 125mgReport a problem
- Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast CancerCompletedPhase 2ETOP IBCSG Partners FoundationNCT02536742With fulvestrant, biomarkers studiedWritten as PalbociclibReport a problem
- PALbociclib CoLlaborative Adjuvant StudyActive, not recruitingPhase 3Alliance Foundation Trials, LLC.NCT02513394Added to adjuvant endocrine therapy (PALLAS)Written as PalbociclibReport a problem
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02738866Continued with fulvestrant after progressionWritten as PalbociclibReport a problem
- Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 2Washington University School of MedicineNCT03389477Before and after chemoradiation in head and neck cancerWritten as PalbociclibReport a problem
- Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic LeukemiaCompletedPhase 1Tanja Andrea GruberNCT04996160With chemotherapy in children's leukaemiaWritten as PalbociclibReport a problem
- Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast CancerCompletedPhase 2Canadian Cancer Trials GroupNCT02630693Two schedules with endocrine therapyWritten as Palbociclib 100mgReport a problem
- Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerCompletedPhase 1PfizerNCT02499146Drug levels in Chinese patientsWritten as PalbociclibReport a problem
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedPhase 2Dana-Farber Cancer InstituteNCT02040857Added to adjuvant endocrine therapyWritten as PalbociclibReport a problem
Showing 20 of 58. See all 58 →
Tested in a combination · 125 — another drug in the study is under test too
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377One matched combination in ComboMATCHWritten as PalbociclibReport a problem
- Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaNot yet recruitingPhase 1/2Second Affiliated Hospital of Nanchang UniversityNCT07926607Written as PalbociclibReport a problem
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingPhase 3American Society of Clinical OncologyNCT06377852Titrated dosing against the indicated doseWritten as Palbociclib 125mgReport a problem
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationEarly Phase 1AHS Cancer Control AlbertaNCT05432518One of five matched drugs in recurrent glioblastomaWritten as PalbociclibReport a problem
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT04693468Added to talazoparib in one armReport a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052One CDK4/6 option, chemotherapy exemption in older womenReport a problem
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06843967With mirdametinib in liposarcomaWritten as PalbociclibReport a problem
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498One CDK4/6 option added to elacestrantWritten as elacestrant, palbociclib, abemaciclib, ribociclibReport a problem
- Novel Molecular Targets and Innovative Therapeutic Perspective in MedulloblastomaRecruitingEarly Phase 1Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06959979One CDK4/6 option in medulloblastomaReport a problem
- Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruitingPhase 2Massachusetts General HospitalNCT02896335Alone or with pembrolizumab in brain metastasesWritten as PalbociclibReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One CDK4/6 option in an HR-positive salivary cohortReport a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606One matched drug in a profiling trial (CAPTUR)Written as PalbociclibReport a problem
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingPhase 1Thomas Jefferson UniversityNCT05627232Added before tazemetostat and CPX-351 in one partWritten as PalbociclibReport a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07299890With HER2 blockade and exemestane before surgeryWritten as Trastuzumab and Pertuzumab Combination with Palbociclib and ExemestaneReport a problem
- An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast CancerNot yet recruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT07300215With HER2 blockade and exemestane, response-adapted, before surgeryReport a problem
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 1/2West China HospitalNCT06753747With afatinib in esophageal cancerWritten as PalbociclibReport a problem
- Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial CarcinomaRecruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06364956With tislelizumab before bladder surgeryReport a problem
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 3Fudan UniversityNCT07005557One CDK4/6 option, chemotherapy-free against chemotherapyReport a problem
- Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.RecruitingPhase 2International Cancer Research Group, United Arab EmiratesNCT05190094With an aromatase inhibitor, response predictedWritten as Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)Report a problem
- Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast CancerRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06207734Continuation against discontinuationReport a problem
Showing 20 of 125. See all 125 →
Beside an established treatment under test · 20 — an approved drug, surgery or radiation is what the study tests
Tested with palbociclib: Radiation 4 · Surgery or a procedure 3 · Fulvestrant 3 · cemiplimab 1 · pembrolizumab 1 · Hydroxychloroquine 1 · Letrozole 1 · Tamoxifen 1
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07748208In every armOptional beside inavolisib and fulvestrant; inavolisib safety studiedWritten as PalbociclibReport a problem
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754In every armMaintenance in a T-DXd-led sequenceWritten as PalbociclibReport a problem
- Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot yet recruitingPhase 3SWOG Cancer Research NetworkNCT07802626One CDK4/6 option while capivasertib is addedReport a problem
- Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not yet recruitingPhase 3UNICANCERNCT07717450One CDK4/6 option continued; a ctDNA-guided switch is testedReport a problem
- Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNot yet recruitingNot applicableWest China HospitalNCT07687225One standard systemic option; primary tumour surgery is testedReport a problem
- Combined Immunotherapies in Metastatic ER+ Breast CancerRecruitingPhase 2Weill Medical College of Cornell UniversityNCT04563507In every armBoth arms take it with letrozole; SBRT is addedWritten as Palbociclib 125mgReport a problem
- PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo StudyRecruitingPhase 2Samsung Medical CenterNCT04819243First in every arm; talazoparib with or without atezolizumab followsReport a problem
- Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06197581One CDK4/6 option beside concurrent radiotherapyReport a problem
- Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT05694871In every armBoth arms take it; cemiplimab is added in liposarcomaWritten as PalbociclibReport a problem
- Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer PatientsActive, not recruitingNot applicableUNICANCERNCT03870919In every armStandard treatment while locoregional treatment is addedWritten as PalbociclibReport a problem
- Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast CancerActive, not recruitingPhase 2City of Hope Medical CenterNCT02778685In every armEvery cohort takes it with letrozole; pembrolizumab is addedWritten as PalbociclibReport a problem
- PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionCompletedPhase 3UNICANCERNCT03079011In every armEvery arm takes it; ctDNA-guided switch to fulvestrant (PADA-1)Written as Palbociclib 125mgReport a problem
- Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast CancerCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03774472In every armWith letrozole while hydroxychloroquine's dose is foundWritten as PalbociclibReport a problem
- Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisCompletedPhase 2Emory UniversityNCT03691493In every armStandard treatment while radiation to bone is addedWritten as PalbociclibReport a problem
- Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerCompletedPhase 2MedSIRNCT02491983In every armBoth arms take it; fulvestrant against letrozole (PARSIFAL)Written as PalbociclibReport a problem
- Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus PalbociclibCompletedEarly Phase 1Shannon PuhallaNCT02913430In every armBoth arms take it; fulvestrant against tamoxifenWritten as PalbociclibReport a problem
- A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCompletedPhase 2Bristol-Myers SquibbNCT04075604In every armEvery arm takes it with anastrozole; nivolumab is addedWritten as PalbociclibReport a problem
- Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesWithdrawnPhase 1Emory UniversityNCT04585724One CDK4/6 option while radiosurgery is studiedWritten as PalbociclibReport a problem
- CIMER: Combined Immunotherapies in Metastatic ER+ Breast CancerWithdrawnPhase 2Weill Medical College of Cornell UniversityNCT04220476In every armBoth arms take it with letrozole; SBRT is addedWritten as Palbociclib 125mgReport a problem
- Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerWithdrawnPhase 2National Cancer Institute (NCI)NCT03377101In every armBoth arms take it with fulvestrant; copanlisib is addedWritten as PalbociclibReport a problem
Beside a new treatment under test · 87 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with palbociclib: giredestrant 6 · ipatasertib 6 · AZD9833 5 · inavolisib 5 · gedatolisib 5 · pyrotinib 3 · capivasertib 2 · vepdegestrant 2
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Partner of new inavolisib in some armsWritten as PalbociclibReport a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336In every armOne CDK4/6 option while new tersolisib is addedWritten as PalbociclibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Partner of new giredestrant in an umbrella cohortWritten as PalbociclibReport a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751One CDK4/6 option beside new saruparib and camizestrantWritten as PalbociclibReport a problem
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingPhase 2PfizerNCT04606446Partner of new PF-07248144Written as PalbociclibReport a problem
- Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05665361In every armPartner of new sasanlimabWritten as PalbocicilibReport a problem
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingPhase 3Celcuity IncNCT06757634Partner of new gedatolisib against ribociclib (VIKTORIA-2)Written as Arm A: Gedatolisib + Palbociclib + FulvestrantReport a problem
- A Phase 1/2a Study of K-1728 in Advanced Solid TumorsNot yet recruitingPhase 1/2KymaThera, Inc.NCT07861932Partner of new K-1728Written as PalbociclibReport a problem
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingPhase 1Bristol-Myers SquibbNCT06997029Partner of new BMS-986500Written as PalbociclibReport a problem
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Partner of new AVZO-021Written as PalbociclibReport a problem
- A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid TumorsNot yet recruitingPhase 1Laekna LimitedNCT07787520Partner of new LAE118Written as PalbociclibReport a problem
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingPhase 2Stephanie BergNCT07123090In every armPartner of new sasanlimab with axitinibWritten as PalbociclibReport a problem
- Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT03454035In every armPartner of new ulixertinibWritten as PalbociclibReport a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Partner of new tersolisibWritten as PalbociclibReport a problem
- A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerRecruitingPhase 1Totus MedicinesNCT05683418Partner of new TOS-358Written as PalbociclibReport a problem
- SNV4818 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Pikavation Therapeutics, Inc.NCT06736704Partner of new SNV4818Written as PalbociclibReport a problem
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingPhase 1/2Forward Pharmaceuticals Co., Ltd.NCT07002177Partner of new FWD1802Written as Palbociclib 125mgReport a problem
- Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07037199One CDK4/6 option after new trastuzumab rezetecanReport a problem
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerRecruitingPhase 2Wenjin YinNCT07180160One CDK4/6 option beside new QL1706Report a problem
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 2West China HospitalNCT07191977In every armPartner of camrelizumab, approved only in ChinaWritten as PalbociclibReport a problem
Showing 20 of 87. See all 87 →
Beside supportive care · 14 — a supportive treatment or test is studied
- Analysis of Circulating Tumor Markers in BloodRecruitingNot applicableInstitut du Cancer de Montpellier - Val d'AurelleNCT04025541Treatment during which blood markers are studiedReport a problem
- Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)RecruitingNot applicableInstitut CurieNCT07491380Treatment while capillary drug monitoring is testedReport a problem
- Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07527806One CDK4/6 option; HER2-PET guides the change of treatmentReport a problem
- Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and PalbociclibRecruitingNot applicableBeneficência Portuguesa de São PauloNCT05277935Treatment while a fitness tracker is testedReport a problem
- Immunomonitoring of Breast Cancer Patients During Systemic TreatmentRecruitingNot applicableCentre Georges Francois LeclercNCT04925856Treatment during which immune cells are monitoredReport a problem
- Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast CancerActive, not recruitingNot applicableCentre Oscar LambretNCT04653740Treatment during which resistance is trackedReport a problem
- Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBCActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03439735Standard treatment during which resistance is studiedReport a problem
- A Study of the Use of Text Message Reminders to Take PalbociclibActive, not recruitingNot applicableMemorial Sloan Kettering Cancer CenterNCT04216576Treatment while text-message reminders are testedReport a problem
- Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine MonotherapyCompletedNot applicablePfizerNCT04736576Treatment during which outcomes and activity are measuredReport a problem
- Analysis of Circulating Tumor Markers in the Blood (ALCINA)CompletedNot applicableInstitut CurieNCT02866149Treatment during which blood markers are studiedReport a problem
- Feasibility of Fasting & Exercise in Pts With HR+ MBCCompletedNot applicableDana-Farber Cancer InstituteNCT04708860Treatment while fasting and exercise are testedReport a problem
- Palbociclib and FES PETCompletedPhase 2University Medical Center GroningenNCT02806050In every armTreatment whose response FES PET predictsWritten as PalbociclibReport a problem
- Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyTerminatedPhase 4Palleos Healthcare GmbHNCT03220178In every armTreatment while eHealth support is testedWritten as PalbociclibReport a problem
- The Resistance and Immune Response to Palbociclib in Breast CancerStatus unknownNot applicableSamsung Medical CenterNCT03401359Treatment during which resistance and immunity are studiedReport a problem
One option of several · 10 — a test or a strategy chooses among drugs
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491One drug the organoid test can chooseWritten as PalbociclibReport a problem
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220One CDK4/6 option with elacestrantWritten as PalbociclibReport a problem
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014One of many targeted options chosen by sequencingWritten as PalbociclibReport a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingPhase 2University of MiamiNCT05826964One switch option guided by blood DNAReport a problem
- Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyTerminatedPhase 2M.D. Anderson Cancer CenterNCT04256941In every armOne CDK4/6 option; fulvestrant is added for ESR1 mutationsWritten as PalbociclibReport a problem
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne of many drugs in individualised combinationsWritten as PalbociclibReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One of many drugs in tailored therapyWritten as PalbociclibReport a problem
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownPhase 2Baodong QinNCT03239015In every armOne target drug in precision therapyWritten as PalbociclibReport a problem
- Biomarker-driven Therapy for MelanomaCompletedNot applicableCharite University, Berlin, GermanyNCT05063058One option in molecular guided therapyReport a problem
- Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownPhase 2Herlev and Gentofte HospitalNCT04644432One drug a tailored kidney cancer strategy can chooseReport a problem
As the comparator · 7 — what is tested is compared with palbociclib
- A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerNot yet recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07894328One comparator choice for new HRS-6209Report a problem
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingPhase 3BeOne MedicinesNCT07492641One comparator choice for new BGB-43395Written as PalbociclibReport a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingPhase 2MedSIRNCT06486883One CDK4/6 option in the comparator against T-DXdReport a problem
- Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialRecruitingPhase 2Henan Cancer HospitalNCT06176534One CDK4/6 option in the comparator against chemotherapyReport a problem
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingPhase 3PfizerNCT06760637One investigator's-choice comparator for new atirmociclibWritten as palbociclibReport a problem
- Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeTerminatedPhase 3SOLTI Breast Cancer Research GroupNCT05207709Comparator for ribociclib in HER2-enriched disease (HARMONIA)Report a problem
- CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDOCompletedPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT03227328One CDK4/6 option in the comparator against chemotherapyReport a problem
Observed · 73 — patients on it are followed, or it is given outside a trial
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingHoffmann-La RocheNCT07347600Beside inavolisib and fulvestrant, observedWritten as PalbociclibReport a problem
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingFundación Santa Fe de BogotaNCT07856225Among CDK4/6 inhibitors, outcomes by subtypeWritten as CDK4/6 InhibitorsReport a problem
- To Identify Primary Resistance to CDK4/6 Inhibitors in Breast CancerRecruitingFondazione Sandro PitiglianiNCT04660435Among CDK4/6 inhibitors, primary resistanceReport a problem
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsRecruitingMayo ClinicNCT06388122A biomarker assay in patients starting CDK4/6 treatmentReport a problem
- Real-world Studies of CDK4/6 InhibitorsRecruitingTianjin Medical University Cancer Institute and HospitalNCT07407439Real-world use in ChinaReport a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingFondazione Policlinico Universitario Campus Bio-MedicoNCT07021911One treatment group in a radiotherapy studyReport a problem
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyRecruitingFondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT06805812Among CDK4/6 inhibitors, outcomes predictedWritten as PalbociclibReport a problem
- A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 InhibitorsRecruitingCliniques universitaires Saint-Luc- Université Catholique de LouvainNCT06171360Gut microbiome during first-line CDK4/6 treatmentReport a problem
- Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.Not yet recruitingHelwan UniversityNCT06338644Gene polymorphisms in Egyptian patientsWritten as PalbociclibReport a problem
- Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer PatientsNot yet recruitingAssiut UniversityNCT06076772Neutropenia risk factorsWritten as PalbociclibReport a problem
- Swedish Ibrance Registries Insights (SIRI)CompletedPfizerNCT04654208Swedish registriesWritten as palbociclibReport a problem
- A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world DatabaseCompletedPfizerNCT06962969Patients receiving it, real-worldWritten as IbranceReport a problem
- A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other OrgansCompletedPfizerNCT06003114Use in CanadaWritten as PalbociclibReport a problem
- A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese MarketCompletedPfizerNCT07096024Post-marketing use with fulvestrant in JapanWritten as palbociclib plus fulvestrantReport a problem
- European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal TherapiesCompletedPfizerNCT05043506First-line treatment patterns in EuropeWritten as Palbociclib + aromatase inhibitorReport a problem
- A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)CompletedPfizerNCT05912933Liver impairment and myelosuppressionReport a problem
- Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBCCompletedPfizerNCT04937660Combinations and outcomes in practiceReport a problem
- Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine TherapyActive, not recruitingMayo ClinicNCT03281902Tumour and blood genetics in patients receiving itReport a problem
- A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in AustraliaCompletedPfizerNCT06624020Real-world use in AustraliaReport a problem
- A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)CompletedPfizerNCT05709158Myelosuppression risks after marketingReport a problem
Showing 20 of 73. See all 73 →
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered2
- Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaNov 9, 2026NCT07926607
- An Open-label, Randomized, Single Oral Dose, Two-period, Two-sequence, Two-way, Crossover Bioequivalence Study on Healthy Adult Male Participants Under Fed Conditions to Compare, Test Product Palbociclib-EVAPHARMA 125 mg Hard Gelatin Capsule, Versus the Reference Product Ibrance™125 mg CapsulesNov 6, 2026NCT07922564
Codes
What other systems call palbociclib · ClinicalTrials.gg INT004770
- MeSH (NLM) C500026palbociclibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G9ZF61LE7GPALBOCICLIBConfirmed FDA, NLM, Wikidata
- RxNorm 1601374Confirmed FDA, Wikidata
- Wikidata Q15269707palbociclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49176PalbociclibOne source FDA
- DrugBank DB09073One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C500026 | palbociclib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G9ZF61LE7G | PALBOCICLIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1601374 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15269707 | palbociclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49176 | Palbociclib | One source FDA |
| DrugBank | DB09073 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.